8-(3-Ethoxyphenyl)-3-[2-[4-(trifluoromethoxy)phenoxy]ethyl]imidazo[1,2-c]pyrimidine-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 8-(3-Ethoxyphenyl)-3-[2-[4-(trifluoromethoxy)phenoxy]ethyl]imidazo[1,2-c]pyrimidine-2-carboxylic acid
• 英文别名: 8-(3-ethoxyphenyl)-3-[2-[4-(trifluoromethoxy)phenoxy]ethyl]imidazo[1,2-c]pyrimidine-2-carboxylic acid
• 化学式: C₂₄H₂₀F₃N₃O₅
• 分子量: 487.4
• InChiKey: JGOIJWBMWSGULE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  95.2
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
  申请人：Hanney Barbara

  公开号：US20140155413A1

  公开（公告）日：2014-06-05

  The present invention is directed to compounds of formula I and 1a: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及公式I和1a的化合物，它们是肌动蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此在治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与失髓鞘或脱髓鞘有关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA的异常活动有关的疾病或紊乱的治疗中有用。